Adamantane derivatives for the treatment of filovirus infection
AssigneeArisan Therapeutics Inc.
InventorsMichael Bruno Plewe, Eric Brown, Vidyasagar Gantla, Gregory Henkel, Kenneth McCormack, Nadezda Sokolova
Life of this patent
Estimating the term…
Abstract
Compounds of structural Formula I were developed for the treatment of infections by filoviruses including Ebolavirus and Marburgvirus, wherein, R1, R2, R3, X and Y are defined in the specification.
Claims20
A method of treating infections associated with Filoviridae enveloped virus, or any virus expressing filovirus glycoproteins to mediate cell entry, comprising administering to a subject in need thereof a composition comprising a therapeutically effective amount of a compound of Structural Formula I
- or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or vehicle, wherein:
- X is C-D, and Y is a bond;
- D is selected from the group consisting of
- R1 is (C6 to C10) aryl, wherein (C to C10) aryl is optionally substituted with at least one R13 group;
- R2 is selected from (C1 to C10) alkyl, (C1 to C10) alkoxy, and —C(O)OR12, wherein
- (C1 to C10) alkyl is optionally substituted with at least one R13 group;
- R3 is selected from hydrogen and (C1 to C10) alkyl;
- each R8 is independently selected from hydrogen and (C1 to C10) alkyl;
- each of the R9a and R9b is independently selected from hydrogen, halogen, (C1 to C10) alkyl, and —C(O)OR12;
- R12 is (C1 to C10) alkyl;
- each R13 is independently selected from hydrogen, OH, nitro, (C1 to C10) alkyl, and (C1 to C10) alkoxy;
- j is independently selected from 0 or 1.
A method of treating infections associated with Filoviridae A enveloped virus, or any virus expressing filovirus glycoproteins to mediate cell entry, comprising administering to a subject in need thereof, composition comprising a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable A carrier, diluent, or vehicle, wherein the compound is selected from the group consisting of:
A compound represented by Structural Formula I
- or a pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier, diluent, or vehicle thereof, wherein:
- X is C-D, and Y is a bond;
- D is selected from the group consisting of
- R1 is selected from (C to C10) aryl, wherein (C to C10) aryl is optionally substituted with at least one R13 group;
- R2 is selected from (C1 to C10) alkyl, (C1 to C10) alkoxy, and —C(O)OR12, wherein (C1 to C10) alkyl is optionally substituted with at least one R13 group;
- R3 is selected from hydrogen and (C1 to C10) alkyl;
- each R8 is independently selected from hydrogen and (C1 to C10) alkyl;
- each of the R9a and R9b is independently selected from hydrogen, halogen, (C1 to C10) alkyl, and —C(O)OR12;
- each of the R12 is independently selected from (C1 to C10) alkyl;
- each R13 is independently selected from hydrogen, OH, nitro, (C1 to C10) alkyl, and (C1 to C10) alkoxy;
- j is independently selected from 0 or 1.
A compound selected from the group consisting of:
Dependencies are inferred from the claim text.